	US 12,364,676 B2
	Compositions and methods for treating retinopathy
Steven Hoffman, Mahwah, NJ (US)
Assigned to YAMO PHARMACEUTICALS LLC, New York, NY (US)
Filed by Yamo Pharmaceuticals LLC, New York, NY (US)
Filed on Jun. 2, 2022, as Appl. No. 17/830,458.
Application 17/830,458 is a division of application No. 15/958,598, filed on Apr. 20, 2018, granted, now 11,351,136.
Claims priority of provisional application 62/488,161, filed on Apr. 21, 2017.
Prior Publication US 2022/0288003 A1, Sep. 15, 2022
Int. Cl. A61K 31/198 (2006.01); A61K 9/00 (2006.01); A61K 31/20 (2006.01); A61K 31/201 (2006.01); A61K 31/4166 (2006.01); A61K 31/55 (2006.01); A61K 45/06 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61P 27/02 (2006.01)

CPC A61K 31/198 (2013.01) [A61K 9/0014 (2013.01); A61K 31/20 (2013.01); A61K 31/201 (2013.01); A61K 31/55 (2013.01); A61K 45/06 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61P 27/02 (2018.01); A61K 31/4166 (2013.01); A61K 2300/00 (2013.01)]

7 Claims

1. A method of treating macular degeneration in a subject comprising administering to a subject in need thereof an effective amount of α-methyl DL-tyrosine.